Urologists and patients show resilience, but we must be better prepared in the future, says urologist R. Jonathan Henderson, MD.
UCC June 2020
Combination therapy is the first-line standard for metastatic renal cell carcinoma.
Patients with cancer are particularly susceptible to negative consequences of COVID-19.
Next-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
